Journal article
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
SM Handunnetti, MA Anderson, K Burbury, PA Thompson, G Burke, M Bressel, J Di Iulio, RJ Hicks, D Westerman, S Lade, C Pott, R Agarwal, R Koldej, D Ritchie, M Dreyling, MA Dawson, SJ Dawson, JF Seymour, AW Roberts, CS Tam
Blood | Published : 2024
Abstract
In the phase 2 clinical trial (AIM) of venetoclax-ibrutinib, 24 patients with mantle cell lymphoma (MCL; 23 with relapsed/refractory [R/R] disease) received ibrutinib 560 mg and venetoclax 400 mg both once daily. High complete remission (CR) and measurable residual disease negative (MRD-negative) CR rates were previously reported. With median survivor follow-up now exceeding 7 years, we report long-term results. Treatment was initially continuous, with elective treatment interruption (ETI) allowed after protocol amendment for patients in MRD-negative CR. For R/R MCL, the estimated 7-year progression-free survival (PFS) was 30% (95% confidence interval [CI], 14-49; median, 28 months; 95% CI, ..
View full abstractRelated Projects (1)
Grants
Awarded by AbbVie
Funding Acknowledgements
The authors thank the patients who participated in this study and their families, referring physicians, study coordinators, Piers Blombery and the Peter MacCallum Molecular Pathology Laboratory, and support staff at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital.This study was supported by Janssen, AbbVie, the Victorian Cancer Agency, the National Health and Medical Research Council of Australia (M.A.A. [1177718] and A.W.R. [1174902; 2011139] ) , the Leukemia and Lymphoma Society (S.-J.D. and M.A.D.) , and the Peter MacCallum Foundation.